Skip to content
Study details
Enrolling now

A Study to Determine the Preferred Dose of Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

University of Rochester
NCT IDNCT05530655ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

30

Study length

about 3.9 years

Ages

18–70

Sex

Male only

Locations

1 site in NY

What this study is about

This trial is testing a treatment called lisinopril to see if it can prevent urinary problems in men with prostate cancer who are receiving radiation therapy. The goal is to find the best dose of lisinopril and understand how it affects urine symptoms, biomarkers, and their connection to those symptoms.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Lisinopril Tablets

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

lisinopril (ACE inhibitor; blocks angiotensin-converting enzyme to lower blood pressure)

Drug routes

oral (Oral Tablet)

Body systems

Oncology